SNSeiji Niho

Seiji Niho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seiji Niho has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study

    by Seiji Niho, Tatsuya Yoshida, Tetsuo Akimoto, Kentaro Sakamaki, Akira Ono, Takashi Seto, Makoto Nishio, Noboru Yamamoto, Toyoaki Hida, Hiroaki Okamoto, et al.


  • Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study

    by Seiji Niho, Yukio Hosomi, Hiroaki Okamoto, Keiji Nihei, Hiroshi Tanaka, Toyoaki Hida, Shigeki Umemura, Koichi Goto, Tetsuo Akimoto, Yuichiro Ohe

    Objectives: We conducted a Phase I/II study of carboplatin, S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients (71 years or older) with unresectable stage III non-small cell lung cancer (NSCLC). Materials and methods: Patients received carboplatin (AUC 3-5) on Day 1 and S-1 (30–40 mg/m2 two times daily) on Days 1–14, every 2 weeks, for up to four cycles, plus concurrent TRT at a total dose of 60 Gy. The primary endpoint for the Phase II study was the 1-year progression-free survival (PFS) rate. Results: Eighteen patients were enrolled in the Phase I study. Febrile neutropenia, a decreased platelet count and esophagitis were dose-limiting toxicities. The recommended doses for the Phase II study were determined to be an AUC of 3 for carboplatin, 40 mg/m2 twice daily for S-1. Twenty-eight patients were evaluated in the Phase II study. The 1-year PFS rate was 57.1% (90% CI 41.6–71.4%), and the median PFS was 16.8 months (95% CI 7.8–not assessable [NA]). The lower limit of the 90% CI for 1-year PFS exceeded the prespecified threshold value of 30%; therefore, the primary endpoint was met. Grades 3–4 toxicities included thrombocytopenia (21%) and hyponatremia (11%). Grade 3 radiation pneumonitis was observed in 18% of patients. No treatment-related deaths were observed. Conclusion: Combination chemotherapy consisting of carboplatin plus S-1 and concurrent TRT had a promising efficacy in elderly patients with locally advanced NSCLC; however, radiation pneumonitis was frequently observed.


  • Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer Thoracic Oncology Research Group (TORG) 0809

    by Seiji Niho, Norihiko Ikeda, Hiroshi Michimae, Kenji Suzuki, Hiroshi Sakai, Takayuki Kaburagi, Katsuo Yoshiya, Koichi Minato, Terufumi Kato, Hiroaki Okamoto, et al.

    Objectives: The TORG0809 study was a multicenter feasibility study of long-term single-agent therapy with S-1 after docetaxel plus cisplatin therapy in patients with completely resected stage II or stage IIIA non-small cell lung cancer. We report the results of the final overall survival (OS) analysis. Patients and Methods: A total of 129 eligible patients received 3 cycles of docetaxel (60 mg/m(2), day 1) plus cisplatin (80 mg/m(2), day 1), followed by S-1 at 40 mg/m(2) twice daily for 14 consecutive days, for > 6 months (maximum, 1 y). Results: At the cutoff date of April 13, 2016, the median follow-up time was 6.0 years. Of the 129 patients, 43 had died, and 74 patients developed disease recurrence or died. The median OS had not been reached. The 5-year OS rate was 71% [95% confidence interval (CI), 62-78]. The 5-year OS rates in the patients with stage II and stage IIIA were 76% and 68%, respectively. The median recurrence-free survival (RFS) duration was 3.4 years (95% CI, 2.3-5.7). The 5-year RFS rate was 44% (95% CI, 36-53). The 5-year RFS rates in patients with stage II and stage IIIA disease were 57% and 38%, respectively. Disease recurrence occurred in 68 patients, and 62 of these patients received second-line chemotherapy. The most common sites of recurrence were the brain (n = 22) and mediastinal lymph nodes (n = 22). Conclusion: The survival data obtained from this study are promising and comparable to those reported from a previous study conducted in Japan.


  • Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study

    by Seiji Niho, Yuichiro Ohe, Hironobu Ohmatsu, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto


  • Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non–Small Cell Lung Cancer

    by Seiji Niho, Hiroshi Nokihara, Keiji Nihei, Tetsuo Akimoto, Minako Sumi, Yoshinori Ito, Kiyotaka Yoh, Koichi Goto, Hironobu Ohmatsu, Hidehito Horinouchi, et al.

    Objectives:We performed a post hoc analysis of progression-free survival (PFS), overall survival (OS), and recurrent sites in patients with locally advanced nonsquamous non-small cell lung cancer who were enrolled in a phase I trial of combination chemotherapy consisting of pemetrexed plus cisplatin with concurrent thoracic radiotherapy.Methods:Patients received pemetrexed (500 mg/m(2)) plus cisplatin (75 mg/m(2)) on day 1 every 3 weeks for 3 cycles plus concurrent thoracic radiotherapy consisting of 60 Gy (n=6) or 66 Gy (n=12); 4 to 6 weeks thereafter, patients received consolidation treatment with pemetrexed (500 mg/m(2)) every 3 weeks for up to 3 cycles. We reviewed the medial records to collect data on progression, recurrent sites, late toxicity, and survival.Results:No late radiation morbidity was observed. Thirteen patients (72%) exhibited disease progression: 8 patients had distant metastases, 8 patients had local recurrence (within the radiation field [n=6], outside the radiation field [n=2], and both [n=1]), and 3 patients had local recurrence plus distant metastases. The median PFS was 10.5 months (95% confidence interval [CI], 8.8-12.3), and the 3-year PFS rate was 28% (95% CI, 7.0-48.6). Ten of the 18 patients died of lung cancer. The median follow-up time for the censored cases was 42.8 months (range, 38.1 to 52.9 mo). The median OS was 27.3 months (95% CI, 13.1-41.6), and the 3-year OS rate was 50% (95% CI, 26.9-73.1).Conclusions:The median PFS and OS in our study were comparable to those of historical chemoradiotherapy controls.


  • Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia

    by Naohiro Watanabe, Seiji Niho, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Hironobu Ohmatsu, Koichi Goto

    The role of second-line chemotherapy in patients with non-small cell lung cancer (NSCLC) and preexisting interstitial pneumonia (IP) previously treated with platinum-based chemotherapy remains uncertain. This study was conducted to elucidate the efficacy and tolerability of second-line docetaxel monotherapy for patients with platinum-refractory advanced (stage IIIB, IV, or relapse) NSCLC and preexisting IP. A total of 35 patients (median age, 67 years) treated with docetaxel monotherapy in a second-line setting following first-line platinum-based chemotherapy between January 2002 and December 2013 were retrospectively reviewed. The overall response rate and disease control rate were 8.6 % [95 % confidence interval (CI) 0–17.9 %] and 37.1 % (95 % CI 21.1–53.1 %), respectively. The median progression-free survival and median overall survival periods were 1.6 months (95 % CI 1.2–2.0 months) and 5.1 months (95 % CI 3.2–6.7 months), respectively. The incidence of acute exacerbation (AE) of IP following docetaxel monotherapy was 14.3 % (5/35 patients). Of the five patients who developed AE of IP, three patients died. The toxicity of this regimen was substantial, with treatment-related deaths occurring in 5 (14.3 %) patients (AE of IP: 3, sepsis: 2). Docetaxel monotherapy has a poor activity and substantial risks when used for the treatment of platinum-resistant NSCLC with IP. Novel therapeutic approaches should be explored in this setting.


    • 1 March 2015
      • Vol. 35  (3) , 1697-701

    Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia.

    by Naohiro Watanabe, Seiji Niho, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Hironobu Ohmatsu, Koichi Goto

    The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP). A total of 67 patients treated with vinorelbine and cisplatin as a first-line chemo therapy between January 2002 and December 2013 were retrospectively reviewed. The overall response rate was 34.3% [95% confidence interval (CI)=22.9%-45.7%). The median progression-free survival, median overall survival, and 1-year survival rates were 3.7 months (95% CI=3.1-4.3 months), 7.4 months (95% CI=5.4-9.4 months), and 22.4% (95% CI=12.4%-32.4%), respectively. The incidence of acute exacerbation of IP following first-line chemotherapy was 10.4%. The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis.


  • Open Access

    Protective Effect of Magnesium Preloading on Cisplatin-induced Nephrotoxicity: A Retrospective Study

    by Tatsuya Yoshida, Seiji Niho, Mayuko Toda, Koichi Goto, Kiyotaka Yoh, Shigeki Umemura, Shingo Matsumoto, Hironobu Ohmatsu, Yuichiro Ohe

    Magnesium supplementation has been reported to have a nephroprotective effect on cisplatin-induced renal dysfunction, but little evidence exists regarding the effect of magnesium preloading before cisplatin administration. We started to include magnesium preloading (8 mEq) in cisplatin-containing treatment regimens in January 2011. The aim of the present study was to evaluate whether magnesium preloading reduces cisplatin-induced nephrotoxicity. We retrospectively reviewed 496 thoracic malignancy patients treated with cisplatin (≥60 mg/m2)-containing regimens as a first-time chemotherapy between January 2009 and December 2011. We compared the incidence of Grade ≥2 serum creatinine elevation according to the Common Terminology Criteria for Adverse Events, version 4.0, between magnesium preloading group (n = 161 [32%]) and non-magnesium preloading group (n = 335 [68%]) during the first cycle and all cycles. The median number of administered cycles was four in both groups. The incidence of Grade ≥2 serum creatinine elevation in magnesium preloading group was significantly lower during both the first cycle and all cycles than in the non-magnesium preloading group (4.9 versus 19.1% during the first cycle, and 14.2 versus 39.7% during all the cycles). A multivariate analysis indicated that magnesium preloading significantly reduced cisplatin-induced nephrotoxicity throughout the entire period from after the first administration (odds ratio: 0.262, 95% confidence interval: 0.106–0.596 during the first cycle, and odds ratio: 0.234, 95% confidence interval: 0.129–0.414 during all cycles). Magnesium preloading before cisplatin administration significantly reduced cisplatin-induced nephrotoxicity.


  • Open Access

    Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer: Thoracic Oncology Research Group Study 0809

    by S Niho, N Ikeda, H Michimae, K Suzuki, H Sakai, T Kaburagi, K Minato, T Kato, H Okamoto, T Seto, et al.

    We conducted a multicentre feasibility study for single agent long-term S-1 chemotherapy following docetaxel plus cisplatin in patients with curatively resected stage II–IIIA non-small cell lung cancer. Patients received three cycles of docetaxel (60 mg m−2) plus cisplatin (80 mg m−2) and then received S-1 (40 mg m−2 twice daily) for 14 consecutive days with a 1-week rest for >6 months (maximum, 1 year). The primary end point was feasibility, which was defined as the proportion of patients who completed eight or more cycles of S-1 chemotherapy. If the lower 95% confidence interval (CI) of this proportion was 50% or more, then the treatment was considered as feasible. The sample size was set at 125 patients. One hundred and thirty-one patients were enrolled, of whom 129 patients were eligible and assessable. In all, 109 patients (84.5%) completed 3 cycles of docetaxel plus cisplatin and 66 patients (51.2%, 95% CI: 42.5–59.8) completed 8 or more cycles of S-1 treatment. Grade 3/4 toxicities during the S-1 chemotherapy included anaemia (7.3%), neutropaenia (3.7%), and anorexia (3.7%). The toxicity level was acceptable, although the results did not meet our criterion for feasibility. Modification of the treatment schedule for S-1 chemotherapy might improve the treatment compliance.


  • Open Access

    Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study

    by Seiji Niho, Hirotsugu Kenmotsu, Ikuo Sekine, Genichiro Ishii, Yuichi Ishikawa, Masayuki Noguchi, Fumihiro Oshita, Shun-Ichi Watanabe, Ryu Nakajima, Hirohito Tada, et al.